Upstream: Make the Right Decisions for Your mAb

BPI Contributor

January 27, 2020

1 Min Read

18-1-Millipore-Insert-Cover-230x300.jpgBioprocess decisions made during upstream operations can be difficult to reverse at later, more costly stages of biologic manufacture. They even can require significant backtracking, wasting precious time, labor, and material. Read this Special Report to learn ways to optimize monoclonal antibody bioprocessing upstream. Specifically, you will learn about

  • different tools that small and emerging biotechnology groups can use to ensure robust cell-line selection

  • novel media formulations designed for intensified upstream processing in perfusion modes

  • mixing and delivery solutions that can streamline media preparation

  • approaches to characterizing effector functions for antibody therapeutics.

Equipped with this information, you will be able to lay the groundwork for downstream success.

Fill out the form below to read the entire report now.

You May Also Like